Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 9,600 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 9,600 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total value of $300,000.00. Following the transaction, the chief financial officer directly owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Friday, March 13th, Christine Mikail Cvijic sold 4,045 shares of Neurogene stock. The stock was sold at an average price of $20.81, for a total value of $84,176.45.

Neurogene Trading Down 1.6%

NGNE stock opened at $30.77 on Friday. The stock has a 50-day moving average price of $23.04 and a 200-day moving average price of $22.07. Neurogene Inc. has a 1-year low of $13.69 and a 1-year high of $37.27. The firm has a market cap of $480.63 million, a PE ratio of -7.26 and a beta of 1.69.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.08. On average, analysts forecast that Neurogene Inc. will post -5.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Canaccord Genuity Group lowered their price objective on Neurogene to $180.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Lifesci Capital assumed coverage on Neurogene in a research report on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Guggenheim assumed coverage on Neurogene in a research report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.00.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Neurogene by 12.8% in the 1st quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock valued at $525,000 after buying an additional 2,950 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in Neurogene by 128.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock valued at $262,000 after purchasing an additional 7,138 shares during the last quarter. Logos Global Management LP acquired a new position in Neurogene during the 4th quarter valued at about $4,017,000. Schonfeld Strategic Advisors LLC acquired a new position in Neurogene during the 4th quarter valued at about $575,000. Finally, Trexquant Investment LP boosted its stake in Neurogene by 9.7% during the 4th quarter. Trexquant Investment LP now owns 43,323 shares of the company’s stock valued at $892,000 after purchasing an additional 3,840 shares during the last quarter. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.